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ABSTRACT: Nesfatin-1 is a recently discovered satiety-inducing adipokine identified in hypothalamic regions that regulates energy
balance. So far, no data exist on NUCB2/nesfatin-1 localization in human and murine chondrocytes. Here, we therefore investigated
NUCB2/nesfatin-1 gene and protein expression in human and murine chondrocytes and the effect of nesfatin-1 on pro-inflammatory
cytokines expression. Peptide localization was performed by laser confocal microscopy, NUCB2 mRNA expression was studied by RT-
PCR and protein secretion was measured by XMap technology and Western blot analysis. First, we demonstrated cytoplasmic
localization of NUCB2/nesfatin-1 peptide in both human and murine chondrocytes. We present evidence that both mRNA and protein
expression of NUCB2 were increased during the differentiation of ATDC5 murine chondrocyte cell line. Furthermore, we demonstrated
that nesfatin-1 induces IL-6 and MIP-1a mRNA expression and protein secretion in ATDC-5 cells challenged with IL-1, and also
increases COX-2 mRNA expression in these cells. Finally, nesfatin-1 provoked a clear induction of pro-inflammatory agents, such as
COX-2, IL-8, IL-6, and MIP-1a in human primary chondrocytes from OA patients.  2014 Orthopaedic Research Society. Published by
Wiley Periodicals, Inc. J Orthop Res 32:653–660, 2014.
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Nesfatin-1 is a recently identified satiety-inducing
adipokine found in hypothalamic regions that regu-
lates energy balance.1 It is a peptide derived from its
precursor protein, non-esterified fatty acid/nucleobin-
din 2 (NUCB2) that is composed by a signal peptide of
24 amino acids and a protein structure containing 396
amino acids. The homology of the amino acids se-
quence of NUCB2 is highly conserved in humans, mice
and rats. Post-translational processing of NUCB2 by
prohormone convertase (PC) produces three cleavage
products: nesfatin-1 (1–82), nesfatin-2 (85–163), and
nesfatin-3 (166–396). The PC recognition sites within
NUCB2 are highly conserved and the cleavage is
predicted to yield the 82, 79, and 231 amino acid
peptides, nesfatin-1, nesfatin-2, and nesfatin-3, respec-
tively. To date, no biological role has been attributed
specifically to nesfatin-2 and nesfatin-3. Several stud-
ies indicated a potential implication of nesfatin-1, the
N-terminal fragment of NUCB2, as an anorexigenic
molecule. In fact, NUCB2/nesfatin-1 is abundantly
expressed in several regions of the hypothalamus that
play key roles in controlling food intake.2 In addition,
it has been showed that NUCB2/nesfatin-1 was able to
reduce food intake in rodents when administrated
either centrally or peripherally.1,3 NUCB2/nesfatin-1
was expressed in gastric endocrine cells4 and recently
the group of Ramanjaneya observed that another
potential source of peripheral nesfatin-1 is adipose
tissue, preferentially the subcutaneous tissue.5 Recent
studies showed the expression of NUCB2/nesfatin-1
mRNA in other peripheral tissues including pancreas,
islets, heart, stomach, and also spinal cord.4,6,7 Very
recently, NUCB2/nesfatin-1 has been identified also in
human and murine cardiomyocytes where it is able to
induce glucose uptake and the mobilization of the
glucose transporter GLUT-4.8 During the writing of
this article, Li et al.9 demonstrated that nesfatin-1
was able to increase bone mineral density of ovariecto-
mized rats, suggesting a pro-osteogenic activity of this
adipokine that would represent a valuable treatment
of bone metabolic diseases such as osteoporosis.
NUCB2/nesfatin-1 has strong similarities in terms of
metabolic actions with other members of adipokine
superfamily, such as leptin, adiponectin, and lipocalin-
2. These factors have been recently identified, by our
group and others, as active players in the regulation of
physiological and pathological processes, such as in-
flammation and immune response in whole joint
tissues and in rheumatic diseases, such as osteoarthri-
tis (OA) and/or rheumatoid arthritis (RA).10–14 Recent
evidence suggests that central nesfatin-expressing
neurons are sensitive to peripheral inflammatory
stimuli and could account for the reduction in food
intake.15 In addition, nesfatin-1 has been supposed to
play a role in the modulation of inflammatory response
in the central nervous system.16,17
To the best of our knowledge, no data exist on
NUCB2/nesfatin-1 localization in human and murine
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chondrocytes and its expression in these cells. We
therefore investigated NUCB2/nesfatin-1 gene and
protein expression in human and murine chondrocytes
and we have also analyzed the effects of nesfatin-1 on
induction of pro-inflammatory factors. Finally, NUCB2
modulation after treatments with classic pro-inflam-




Fetal bovine serum (FBS), human transferrin, sodium sele-
nite were purchased from Sigma (St. Louis, MO). Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F-12 medium,
Dulbecco’s modified Eagle’s medium (DMEM), trypsin-EDTA,
l-glutamine and antibiotics were purchased from Lonza
(Verviers, Belgium). Nesfatin-1 (1–82) was purchased from
Phoenix Pharmaceuticals (Karlsruhe, Germany). Immuno-
Pure normal goat serum and TOPRO-3 iodide from Invitro-
gen (Carlsbad, CA). Mowiol was obtained from Calbiochem
(Darmstadt, Germany).
Cell Culture and Differentiation
The murine chondrogenic cell line ATDC-5 (purchased from
RIKEN Cell Bank, Tsukuba, Japan) was cultured in DMEM–
Ham’s F-12 medium supplemented with 5% FBS, 10mg/ml
human transferrin, 3 108M sodium selenite, and anti-
biotics (50units/ml penicillin and 50mg/ml streptomycin).
Chondrogenic ATDC-5 cells were differentiated into mature
and hypertrophic chondrocytes, as previously described.18
Briefly, these cells undergo a late differentiation phase,
becoming hypertrophic, calcifying chondrocytes that synthesize
type X collagen and osteopontin, a marker of terminal
chondrocyte differentiation. The differentiation from Days 0 to
21 was further evidenced by sequential increases in type II
collagen, aggrecan, and type X collagen mRNAs. The early and
mature chondrocyte marker type II collagen was expressed in
undifferentiated ATDC5 cells; the level began to increase at
Day 3, peaked at Days 7–10 and gradually declined after Day
15. The expression profile of aggrecan mimicked that of type II
collagen but with a slight delay of a couple of days. The decline
in expression of both chondrocyte markers coincided with the
onset of late-stage chondrocyte differentiation. The expression
of the hypertrophic chondrocyte marker type X collagen began
Figure 1. Basal expression evaluated by RT-PCR of NUCB2 mRNA (panel A) in human primary chondrocytes (line c), T/C-28a2
human cell line (line b) and ATDC-5 murine chondrocytes (line a). Amplicons were electrophoresed on 1.8% agarose gel, stained with
ethidium bromide and visualized with a high definition CCD camera. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression
is also shown (lines d, e and f). NUCB2 protein expression was reported in (panel B). Cytoplasmic localization of NUCB2/nesfatin-1 in
human primary chondrocytes and ATDC-5 by laser confocal microscopy were showed in (panel C).
654 SCOTECE ET AL.
JOURNAL OF ORTHOPAEDIC RESEARCH MAY 2014
at Days 12 and 13. The expression patterns of these early and
late chondrocyte markers were consistent with previous find-
ings in ATDC5 cells regarding in vivo chondrocyte differentia-
tion. We do not illustrate findings regarding the differentiation
of ATDC5 cells because they are extensively reported in
literature.19 T/C-28A2 human immortalized chondrocytes were
a kind gift of Dr. Mary B. Goldring (Hospital for Special
Surgery, NYC, USA). Primary chondrocytes were harvested
from human OA articular cartilage samples obtained from
articular joints of patients undergoing total knee replacement
surgery as previously described.11,14,18 All experiments were
performed in the first passage of culture.
Cell Treatments, Protein Extraction, and Western Blot Analysis
ATDC-5 were plated at a density of 3 105 cells/well in 6-
well plates and incubated with IL-1 0.05 ng/ml and nesfatin-
1 1mM during 24h at 37˚C in serum-free media. Human
primary chondrocytes were seeded at a density of 3 105
cells/well in 6-well plates and treated with nesfatin-1 300nM
during 24h at 37˚C in serum-free media.
Proteins were extracted using a NucleoSpin kit
(Macherey-Nagel, Düren, Germany), according to the manu-
facturer’s instructions. SDS-PAGE and blotting procedure
were carried on as previously described.20 Immunoblots were
incubated with the appropriate antibody (anti-nesfatin-1 (1–
82) antibody, Phoenix Pharmaceuticals) and visualized with
an Immobilon Western Detection kit (Millipore, MA) using
horseradish peroxidase-labeled secondary antibody. To con-
firm equal loading in each sample, the membranes were
stripped in glycine buffer at pH 2 and re-blotted with anti-b-
actin antibody (Sigma). Images were captured and analyzed
with an EC3 imaging system (UVP).
mRNA Isolation and RT-PCR
Murine and human MIP-1a, murine and human IL-6, murine
and human COX2 and human IL-8 mRNA levels were
determined using SYBR Green-based quantitative PCR.
Murine and human NUCB2 mRNA levels were determined
using FAM Green-based quantitative PCR. RNA was
extracted using a NucleoSpin kit (Macherey-Nagel), according
to the manufacturer’s instructions. For relative quantifica-
tion, we performed an RT reaction with a Thermo Scientific
Verso cDNA Synthesis Kit (42˚C for 30min, followed by an
incubation at 95˚C for 2min). RT-PCR was performed in a
Stratagene MX3005P thermal cycler using a standard proto-
col (95˚C for 10min followed by 40 cycles for 15 s of denatur-
ation at 95˚C and 1min annealing/extension at 60˚C), a
SABiosciences Master Mix and specific primers (for mouse
MIP-1a, 112bp, PPM02949E, reference position 436, Gen-
Bank accession no. NM_011337.2; for mouse IL-6, 178bp,
PPM03015A, reference position 73, GenBank accession no.
NM_031168.1; for mouse GAPDH, 140bp, PPM02946E, refer-
ence position 309–328, GenBank accession no. NM_008084.2;
for human MIP-1a, 114bp, PPH00566E, reference position
124, GenBank accession no. NM_002983.2; for human
GAPDH, 175bp, PPH00150E, reference position 1287–1310,
GenBank accession no. NM_002046.3; for human IL-6,
160bp, PPH00560B, reference position 755, GenBank acces-
sion no. NM_000600.3; for mouse COX-2 135bp, PPM03647E,
reference position 955, GenBank accession no. NM_292547;
for human COX-2, 63pb, PPH01136F, reference position
1502, GenBank accession no. NM_000963.2; for human IL-8,
126pb PPH00568A, reference position 326, GenBank acces-
sion no. NM_000584.3). Murine NUCB2 was from SOLARIS,
Thermo Scientific. Results of comparative RT-PCR experi-
ments were analyzed using MxPro software (Stratagene, CA).
Laser Confocal Microscopy
ATDC-5 cells and human primary chondrocytes have been
seeded at a density of 1 105 cells/well on a coverslip in 24-
well plates in cultured media. After adhesion, we have
removed cultured media and we have added formaldehyde
4% in PBS (phosphate buffered saline) during 20min at room
temperature. After three washes with PBS we have blocked
non-specific binding sites with BSA/PBT-T (0,2% BSA;
Tween-20; Triton-100; serum 5%; PBS 1X) during 30min and
next we have incubated with anti-nesfatin antibody 1:500
overnight at 4˚C in blocking solution. Next day, we have
washing four times with PBS 1X and we have added
secondary antibody CyTM 3-conjugated affinipure donkey
anti-rabbit IgG (HþL) 1:500 45min at 37˚C in blocking
solution. After four washes with PBS, we have added
TOPRO-3 1:500 10min in darkness at room temperature,
next we have washed three times in PBS and we have
mounted samples in slides using Mowiol. The next day we
have acquired images by LEICA DMIRE2 confocal microsco-
py using a 63X objective, pixel resolution 512 512, scan
speed 400Hz. Negative controls were performed with non-
specific rabbit IgG primary antibody obtaining no fluores-
cence signals (data not shown).
BioPlex Assay
BioPlex Pro Mouse cytokine (BioRad, Hercules, CA) assay
have been performed to evaluate the effect of nesfatin-1 on
inflammatory cytokines IL-6 and MIP-1a in ATDC-5 cells
challenged with IL-1. Data have been analyzed with the
BioPlex Manager 6.1 software generating 5-para meter
logistic curve fit.
Figure 2. NUCB2 mRNA expression during ATDC-5 differenti-
ation after 7, 14, and 21 days. Values are the meanSEM of at
least 4 independent experiments. p< 0.001 vs. Control. Cell
lysates underwent western blot analysis using NUCB2/nesfatin-1
antibody. b-actin was used as a loading control.
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Statistical Analysis
Data are reported as the meanSEM of at least three
independent experiments, each with at least three indepen-
dent observations. Statistical analysis was performed using
analysis of variance followed by the Student-Newman-Keuls
test or Bonferroni multiple comparison test using the
Prism computerized package (GraphPad Software, La Jolla,
CA). p values less than 0.05 were considered significant.
RESULTS
NUCB2/Nesfatin-1 Basal Expression in Murine and Human
Chondrocytes
NUCB2 mRNA expression was detected in both
mouse and human chondrocytes. As shown in Figure
1A, RT-PCR analysis showed a high expression of
NUCB2 in human primary chondrocytes (line c), in a
human immortalised chondrocyte cell line T/C-28a2
(line b), and ATDC-5 murine chondrocytes (line a).
Furthermore, western blot analysis confirmed NUCB2/
nesfatin-1 protein expression in these cells (Fig. 1B).
Finally, by laser confocal microscopy, we have demon-
strated cytoplasmic localization of NUCB2/nesfatin-1
in both human and murine chondrocytes (Fig. 1C).
NUCB2 mRNA and Protein Production During ATDC-5
Differentiation
As shown in Figure 2, NUCB2 mRNA expression
increased during the process of differentiation of
ATDC-5 cells. This increase is highly significant after
7, 14, and 21 days of differentiation in comparison to
undifferentiated cells (Day 0) (Fig. 2 upper panel).
This effect was also evaluated in terms of protein
expression as reported in Figure 2 (lower panel).
Figure 3. Human mRNA expression of IL-8 (A), IL-6 (B), MIP-1a (C), and COX-2 (D) after treatment with nesfatin-1 300nM during
24h in human primary chondrocytes from OA patients. Values are the meanSEM of at least 4 independent experiments. p< 0.05 vs.
Control.
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Nesfatin-1 Induces Pro-Inflammatory Mediators in Human
Primary Chondrocytes from OA Patients
As showed in Figure 3, nesfatin-1 significantly in-
creased IL-8, IL-6, COX-2, and MIP-1a mRNA expres-
sion in human primary chondrocytes (p< 0.05).
Nesfatin-1, in OA human primary chondrocytes, is
able to induce pro-inflammatory cytokines.
Effect of IL-1 and TNF-a on NUCB2 mRNA and Protein
Expression in ATDC-5 Differentiated Cells and Human
Primary Chondrocytes from OA Patients
As shown in Figure 4A, ATDC-5 differentiated (14
days) cells treated with different doses of IL-1 (0.1 and
0.5 ng/ml) during 24h showed a clear and significant
increase in NUCB2 mRNA expression as well as
protein synthesis. A similar effect was observed when
cells were stimulated with TNF-a (0.1, 1. and 10ng/
ml; Fig. 4B) during 24h. In addition, as shown in
Figure 4C NUCB2 protein expression is increased also
in OA human primary chondrocytes after 24h stimula-
tion with IL-1 (0.1 and 0.5 ng/ml) and TNF-alpha (1
and 10ng/ml; Fig. 4D).
Nesfatin-1 Potentiates the Induction of MIP-1a and IL-6 in
ATDC-5 Chondrocytes Challenged with IL-1
To gain further insight into the potential pro-inflam-
matory activity of nesfatin-1 we have evaluated the
induction of two relevant mediators of inflammation in
cultured ATDC-5 stimulated with nesfatin-1 alone or
in combination with IL-1. As shown in Figure 5A,
nesfatin-1 alone (at a dose of 1mM) was not able to
induce IL-6 in ATDC-5 cells. On the contrary, IL-1 (at
a dose of 0.05ng/ml) was a frank inducer of IL-6 in
ATDC-5 cultured cells. When the cells have been
stimulated with a combination of IL-1 and nesfatin-1,
the expression of IL-6 was significantly higher than in
the cells stimulated with IL-1 and nesfatin-1 alone.
Noteworthy, nesfatin-1 was also able to exert a
similar activity on other inflammatory mediators such
as MIP-1a (Fig. 5B). These results were confirmed also
in terms of mRNA expression (Fig. 5C and D). To note,
Figure 4. Mouse NUCB2 mRNA and protein expression after IL-1 (0.1 and 0.5 ng/ml) treatment for 24h in ATDC-5 differentiated
cells (14 days) cells (panel A). Mouse NUCB2 mRNA and protein expression after TNF-a (0.1, 1, and 10ng/ml) treatment for 24h in
ATDC-5 differentiated (14 days) cells (panel B). Human NUCB2 protein expression after IL-1 (0.1 and 0.5 ng/ml; Panel C), and TNF-a
(1 and 10ng/ml; Panel D) treatment for 24h in human primary chondrocytes from OA patients. b-actin was used as a loading control.
Values are the meanSEM of at least 4 independent experiments. p<0.001 vs. Control; p<0.01 vs. Control; p< 0.05 vs. Control.
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nesfatin-1 was also able to potentiate COX-2
mRNA expression in ATDC-5 cells challenged with
IL-1 (Fig. 5E).
DISCUSSION
NUCB2/nesfatin-1 has been identified for the first
time in the hypothalamus as a factor that regulates
energy balance. However, peripheral production of
this peptide has been also reported. In fact, NUCB2
mRNA was expressed in gastric endocrine cells4 but
also in other peripheral tissues including pancreas,
heart and spinal cord.6,7 Very recently, the group of
Ramanjaneya5 showed that human and murine adi-
pose tissue is able to produce NUCB2/nesfatin-1,
suggesting that this anorexigenic molecule is a novel
adipokine. Nesfatin-1 protein levels are high in diet-
induced obese mice, and human plasma nesfatin-1
correlated positively with increasing BMI. Some lines
of evidence suggest that members of adipokine super-
family, such as leptin, adiponectin, lipocalin-2, and
many other, exert relevant actions as key players of
the complex network of soluble mediators involved in
the pathophysiology of cartilage degenerative dis-
eases. Thus, we have examined NUCB2/nesfatin-1
expression and secretion in these cells. To the best of
our knowledge, this is the first time that, NUCB2
mRNA and protein expression is detected in human
primary chondrocytes and murine ATDC-5 chondro-
cytes. Human and murine chondrocytes showed cyto-
plasmic localization of NUCB2/nesfatin-1. We also
showed, for the first time, that NUCB2 mRNA and
protein expression was increased during the process
of ATDC-5 cells into mature chondrocytes. These data
suggested that this peptide might play a role in
cartilage maturation and in the complex mechanisms
of chondrocyte development and differentiation. The
strong significant increase, as differentiation pro-
gressed, went in parallel with formation of cartilage
nodules and enhancement of mineralization, charac-
teristic signs of differentiation of ATDC-5 cells. To-
gether, these data suggest that NUCB2/nesfatin-1
might be a marker of late-phase chondrogenic differ-
entiation and might affect endochondral ossification.
To this regard, and possibly in agreement with data
reported by our group, Li et al.9 reported that
nesfatin-1 promotes osteogenesis by increasing bone
mineral density in ovariectomized rats. To note,
nesfatin-1 also increased mineralization in MC3T3
Figure 5. Mouse IL-6 protein secretion (panel A) and mRNA expression (panel C) after treatment with nesfatin-1 (1mM) alone or in
combination with IL-1 0.05ng/ml during 24h. Mouse MIP-1a protein secretion (panel B) and mRNA expression (panel D) after
treatment with nesfatin-1 (1mM) alone or in combination with IL-1 0.05ng/ml during 24h. Mouse COX-2 mRNA expression (panel E)
after treatment with nesfatin-1 1mM alone or in combination with IL-1 0.05ng/ml during 24h. Values are the meanSEM of at least 3
independent experiments. p< 0.001 vs. Control; p< 0.01 vs. Control; p<0.05 vs. Control.
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pre-osteoblastic cells and encumbered osteoclastic
differentiation of RAW 264.7 macrophages.
Apart from the first time report of the constitutive
expression of NUCB2/nesfatin-1 in chondrocytes and
its modulation along chondrocyte differentiation, our
study makes another novel observation, that nesfatin-
1 is able to significantly induce chemotactic and pro-
inflammatory mediators such as IL-8, MIP-1a, IL-6,
and COX-2. These factors are also induced by other
adipokines (i.e., leptin and adiponectin in OA chondro-
cyte) suggesting that nesfatin-1 may participate, to-
gether with other previously described adipokines, in
the pathogenesis and/or progression of inflammatory
complications of cartilage degenerative diseases. To
note, in ATDC-5 cells nesfatin-1 alone is not able to
modulate neither IL-6 nor MIP-1a and COX-2. Howev-
er, when cells were stimulated with a combination of
nesfatin-1 and IL-1, a clear potentiation of response
was observed. This synergy and/or potentiation, is not
new in the adipokine superfamily. Actually, other
adipokines (i.e., leptin) showed similar properties,
being inactive alone but very active working in syner-
gy with other cytokines.11 The apparent discrepancy
in the way of response between human and murine
ATDC-5 cells is possibly due to the fact that OA
chondrocytes can be considered as cells whose re-
sponse is influenced by long term exposition to the
inflammatory milieu existing in OA. On the contrary,
ATDC-5 cells, when stimulated with nesfatin-1 alone,
can be considered as cells without any previous
exposition to inflammatory environment. In agreement
with observation in human OA cells, there is the
evidence that in ATDC-5 cells challenged with IL-1, a
classic pro-inflammatory cytokine, nesfatin-1 is able to
increase the inflammatory response in terms of in-
creased synthesis and expression of chemotactic fac-
tors (IL-8, MIP-1a), cytokines (IL-6), and prostanoids
(COX-2).
Regarding the influence of inflammatory milieu,
another novel aspect of our results is the expression
profile of NUCB2/nesfatin-1 in cells treated with IL-1
and TNF-a, two classic cytokines that are involved in
OA and RA. This finding indicates that IL-1 and TNF-
a, released from joint tissue, are involved from one
side in the induction of pro-inflammatory mediators
and proteinase that promote the destruction of carti-
lage matrix, as widely reported in the literature. On
the other hand, these cytokines may alter constitutive
expression of nesfatin-1 in chondrocytes that, in an
autocrine or paracrine manner may perpetuate the
inflammatory response by modulating the synthesis
and or expression of chemotactic factors, cytokines, or
prostanoids.
In conclusion, our data show, for the first time,
that NUCB2/nesfatin-1 is synthesized and produced
by human and murine chondrocytes. In addition,
NUCB2/nesfatin-1 production was increased during
the chondrocyte differentiation process and after the
stimulation with pro-inflammatory mediators such as
IL-1 and TNF-a. Furthermore, nesfatin-1 induces
pro-inflammatory cytokines alone in OA human
primary chondrocytes and in combination with IL-1
in murine chondrocytes. Our present study revealed
novel basis for understanding the mechanism/s by
which novel adipokines, such as nesfatin, may con-
tribute to the function and regulation of chondrocyte
pathophysiology.
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